XML 71 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Mar. 19, 2021
USD ($)
$ / shares
shares
Feb. 14, 2020
USD ($)
shares
Nov. 01, 2019
USD ($)
product
shares
Mar. 10, 2021
shares
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Consideration            
Number of products acquired | product     4      
Cash payment for business acquisition         $ 15,520 $ 5,850
Acquisition related costs         2,919 2,348
Recognized amounts of identifiable assets acquired, and liabilities assumed            
Goodwill         $ 65,802 $ 28,090
The Pediatric Portfolio            
Consideration            
Cash payment for business acquisition     $ 4,500      
The Pediatric Portfolio | Series G Convertible Preferred Stock            
Consideration            
Total shares issued (in shares) | shares     9,800,000      
Innovus            
Consideration            
Fair value of Contingent Value Rights   $ 16,000        
Innovus | Aytu Common Stock            
Consideration            
Total shares issued (in shares) | shares   380,000        
Innovus | Series H Convertible Preferred Stock            
Consideration            
Shares issued in exchange for warrants | shares       2,000,000    
Neos Therapeutics, Inc.            
Consideration            
Cash payment for business acquisition $ 15,383          
Total shares issued (in shares) | shares 5,471,804          
Estimated fair value per share of Aytu common stock (in dollars per share) | $ / shares $ 9.73          
Estimated fair value of equity consideration transferred $ 53,241          
Acquisition related costs 2,900          
Issuance costs 100          
Estimated fair value of replacement equity awards 432          
Total consideration transferred 69,056          
Recognized amounts of identifiable assets acquired, and liabilities assumed            
Cash and cash equivalents 15,722          
Accounts receivables, net 24,696          
Inventory, net 10,984          
Prepaid expenses and other current assets 2,929          
Operating leases right-to-use assets 3,515          
Property, plant and equipment 5,519          
Intangible assets 56,530          
Other long-term assets 149          
Accounts payable and accrued other expenses (56,718)          
Short-term line of credit (10,707)          
Long-term debt, including current portion (17,678)          
Operating lease liability (3,515)          
Other long-term liabilities (82)          
Total identifiable net assets 31,344          
Goodwill $ 37,712          
Minimum | Neos Therapeutics, Inc.            
Consideration            
Estimated useful lives 1 year          
Maximum | Neos Therapeutics, Inc.            
Consideration            
Estimated useful lives 17 years          
Innovus            
Consideration            
Ownership percentage by parent   100.00%        
Neos Therapeutics, Inc.            
Consideration            
Ownership percentage by parent 100.00%